Ep162: Sean McClain on AI for Biologic Drug Discovery
Jul 16, 2024
auto_awesome
Sean McClain, CEO of Absci, discusses using AI to speed up biologic drug discovery. Topics include the upcoming clinical testing of an antibody drug for inflammatory bowel disease in 2025, integrating AI into drug discovery, the creative aspects of biologic drug discovery, engineering E. coli for biologic therapies, evolving business models in biologic drug discovery, unexpected discoveries in drug compound affinity, and revolutionizing drug discovery with AI-generated biologics.
Absci uses AI to accelerate biologic drug candidate discovery.
AI-driven platform optimizes antibody design for challenging diseases.
Absci targets TL1A protein for best-in-class antibody therapies in inflammatory bowel disease.
Deep dives
Sean McLean's Journey from Startup to Biotech Advancements
Sean McLean is the founder of AvSci, a biotech company specializing in antibody drug discovery. AvSci, initially a scrappy garage biotech, leveraged E. coli assays for testing antibodies quickly and cost-effectively. Embracing AI, the company aimed to accelerate biologic drug candidate discovery. With McLean as CEO, AvSci has raised over $530 million, preparing to advance their antibody drug candidate for inflammatory bowel disease into clinical trials in 2025.
Innovative Approach to AI in Drug Discovery
AvSci's pioneering approach incorporates AI for rapid drug candidate development. By using AI to design antibodies with specific attributes, AvSci reduces time and costs significantly. The company's AI-driven platform enables the design of novel biologics targeting challenging diseases like inflammatory bowel disease. AvSci's active learning loop shortens drug development timelines and optimizes antibody design.
Strategic Decision Making in Developing Drug Candidates
AvSci strategically targets the TL1A protein for inflammatory bowel disease, aiming to create best-in-class antibody therapies. By focusing on immunogenicity, potency, and broader patient response profiles, AvSci strives to differentiate its antibody offering. The company engineers antibodies with improved half-lives and less frequent dosing to enhance patient outcomes.
Progress towards Clinical Trials and Potential Impact on the Industry
AvSci plans to enter clinical trials in 2025, with an interim readout expected later that year. The company aims to deliver innovative therapies through efficient AI-driven drug discovery. By potentially surpassing existing antibody therapies in efficacy and patient response, AvSci seeks to revolutionize the biotech industry and ultimately enhance patient care.
Long-Term Vision of AvSci: Becoming the Next Regeneron
Sean McLean envisions AvSci as the next Regeneron, leveraging AI to fundamentally transform antibody discovery and personalized medicine. Through strategic target selection, enhanced drug design, and novel biology insights, AvSci strives to positively impact patients' lives. The company's dedication to technology, patient-centered innovations, and future AI prediction of biology position it as a pioneer in biotech advancement.